Cargando…

Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity

Examine Setmelanotide use in patients with rare genetic variants that disrupt the melanocortin pathway. RECENT FINDINGS: Between February 2017 and September 2018, 10 participants with pro-opiomelanocortin (POMC)/ proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency and 11 participants wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trapp, Christine M., Censani, Marisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Special Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973437/ https://www.ncbi.nlm.nih.gov/pubmed/36722447 http://dx.doi.org/10.1097/MED.0000000000000798

Ejemplares similares

Pediatric Obesity Algorithm: A Practical Approach to Obesity Diagnosis and Management
por: Cuda, Suzanne E., et al.
Publicado: (2019)

Assessment, differential diagnosis, and initial clinical evaluation of the pediatric patient with obesity: An Obesity Medical Association (OMA) Clinical Practice Statement 2022
por: Cuda, Suzanne E., et al.
Publicado: (2022)

FRI082 Impact Of Setmelanotide On Metabolic Parameters And Vital Signs In Patients With Hypothalamic Obesity
por: Jennifer Abuzzahab, M, et al.
Publicado: (2023)

ODP607 Long-term Efficacy of Setmelanotide in Patients With POMC or LEPR Deficiency Obesity
por: Clément, Karine, et al.
Publicado: (2022)

SAT656 Weight Reduction After 6 Months Of Setmelanotide Treatment In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)

Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency
por: Kühnen, Peter, et al.
Publicado: (2022)

Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome
por: Haws, Robert, et al.
Publicado: (2020)

Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide
por: Wabitsch, Martin, et al.
Publicado: (2022)

ODP605 Body Mass Index and Weight Reductions in Patients With SRC1 Genetic Variant Obesity After 1 Year of Setmelanotide
por: Martos-Moreno, Gabriel Á, et al.
Publicado: (2022)

ODP606 Long-term Efficacy of Setmelanotide in Patients With Bardet-Biedl Syndrome
por: Argente, Jesús, et al.
Publicado: (2022)

Clinical review: Guide to pharmacological management in pediatric obesity medicine
por: O'Hara, Valerie, et al.
Publicado: (2023)

FRI066 Treatment History And Comorbidities Reported By Patients With Hypothalamic Obesity Treated With Setmelanotide In A Phase 2 Trial
por: Roth, Christian L, et al.
Publicado: (2023)

Efficacy and Safety of Setmelanotide, a Melanocortin-4 Receptor Agonist, for Obese Patients: A Systematic Review and Meta-Analysis
por: Ferraz Barbosa, Bárbara, et al.
Publicado: (2023)

Timing of Onset of Adverse Events With Setmelanotide, an MC4R Agonist, in Patients With Severe Obesity Due to LEPR or POMC Deficiency
por: Clément, Karine, et al.
Publicado: (2021)

RF24 | PSUN91 Body Mass Index and Weight Reduction in Patients With SH2B1 Genetic Variant Obesity After One Year of Setmelanotide
por: Argente, Jesús, et al.
Publicado: (2022)

FRI065 Trial Design Of A Double-blind, Randomized, Placebo-controlled, Phase 3 Study Of Setmelanotide In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)

Genotype–phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia
por: Reijman, M.D., et al.
Publicado: (2023)

Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies
por: Wabitsch, Martin, et al.
Publicado: (2022)

Growth Failure and Excessive Weight Gain in a 10 Year Old Male With Obesity: Approach to Diagnosis, Management, and Treatment of Acquired Hypothyroidism
por: Schumaker, Tiffany, et al.
Publicado: (2018)

Composite Pheochromocytoma: A Rare Form of Tumor
por: Lakshminarayana, G. R.
Publicado: (2019)

Genetic testing for rare pediatric lung disorders: The promise and the pitfalls
por: Nogee, Lawrence M.
Publicado: (2020)

Metabolic, behavioral health, and disordered eating comorbidities associated with obesity in pediatric patients: An Obesity Medical Association (OMA) Clinical Practice Statement 2022
por: Cuda, Suzanne E., et al.
Publicado: (2022)

Progress and promise in understanding the genetic basis of common diseases
por: Price, Alkes L., et al.
Publicado: (2015)

Rare Genetic Forms of Obesity: Clinical Approach and Current Treatments in 2016
por: Huvenne, Hélène, et al.
Publicado: (2016)

Beneficial Effects of Setmelanotide in a 5-Year-Old Boy With POMC Deficiency and on His Caregivers
por: Dubern, Beatrice, et al.
Publicado: (2023)

Structures of active melanocortin-4 receptor–Gs-protein complexes with NDP-α-MSH and setmelanotide
por: Heyder, Nicolas A., et al.
Publicado: (2021)

Social consequences and genetics for the child with overweight and obesity: An obesity medicine association (OMA) clinical practice statement 2022
por: Cuda, Suzanne, et al.
Publicado: (2022)

Obesity pillars roundtable: Obesity and individuals from the Mediterranean region and Middle East
por: Bays, Harold Edward, et al.
Publicado: (2022)

The promise and perils of Unit 731 data to advance COVID-19 research
por: Su, Zhaohui, et al.
Publicado: (2021)

OR10-1 Body Mass Index and Weight Reductions in Patients With Obesity Due to Heterozygous Variants in POMC, PCSK1, and LEPR After 1 Year of Setmelanotide
por: Farooqi, Sadaf, et al.
Publicado: (2022)

The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis
por: Salmon, Kristiana, et al.
Publicado: (2022)

Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
por: Collet, Tinh-Hai, et al.
Publicado: (2017)

Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports
por: Censani, Marisa, et al.
Publicado: (2015)

Vitamin D Deficiency Associated With Markers of Cardiovascular Disease in Children With Obesity
por: Censani, Marisa, et al.
Publicado: (2018)

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
por: Ryan, Donna H.
Publicado: (2021)

The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design
por: Haws, Robert M., et al.
Publicado: (2021)

A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation
por: Reininghaus, Nanina, et al.
Publicado: (2022)

A Phase 3 Trial in Participants With Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide
por: Haws, Robert, et al.
Publicado: (2021)

The power of stories in Pediatrics and Genetics
por: Opitz, John M., et al.
Publicado: (2016)

Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome
por: Ervin, Claire, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lmqujuh0gd7h4lorfq3q8dt46v